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Background
All-trans retinoic acid (ATRA)/anthracycline chemotherapy is beneficial in newly diag-
nosed acute promyelocytic leukemia (APL); however, it is important to identify patients 
with high-risk disease to increase the cure rate. We investigated the outcome of ATRA/an-
thracycline chemotherapy and clinicobiological correlations of FLT3/ITD and NPM1 muta-
tions in APL patients.
Methods
Induction therapy included oral ATRA (45 mg/m
2/day) and idarubicin (12 mg/m
2/day, in-
travenous, on days 2, 4, and 6). Patients achieving complete remission (CR) received 3 
courses of ATRA combined with reinforced consolidation therapy. Mutations were ana-
lyzed using GeneScan and polymerasae chain reaction assays of bone marrow samples 
obtained from patients at diagnosis.
Results
Forty-five (84.9%) of 53 eligible patients achieved CR. The overall relapse rate was 8.9%, 
and the 3-year overall survival (OS) and leukemia-free survival (LFS) were 84.9±4.9%
and 77.5±6.0%, respectively. The NPM1 mutation was not found in any patient, while 
the FLT3/ITD mutation was found in 10 (20.0%) patients. Of the FLT3/ITD+ patients, 80% 
belonged to the high-risk group, defined according to the presenting WBC and platelet 
counts. Among the patients who achieved CR, those who were FLT3/ITD+ had a higher 
relapse rate than those FLT3/ITD-. FLT3/ITD+ patients also had a significantly lower 3-year 
LFS than FLT3/ITD- patients. Multivariate analysis of the LFS showed that the FLT3/ITD 
mutation was independently associated with a shorter overall LFS, after adjusting for pre-
treatment risk stratification.
Conclusion
This study investigated the clinical outcome of newly diagnosed APL patients treated with 
ATRA/anthracycline chemotherapy. Patients carrying the FLT3/ITD mutation had more ag-
gressive clinical features and a poorer clinical outcome.
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INTRODUCTION
  Most patients with acute promyelocytic leukemia (APL) 
are now successfully treated with all-trans retinoic acid 
(ATRA) and anthracycline-based chemotherapy as first line 
therapy. A randomized study comparing the simultaneous 
administration of ATRA and anthracycline chemotherapy 
with the sequential administration of these therapeutic 
agents revealed that the former was more effective than Korean J Hematol 2011;46:24-30.
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the latter [1]. The complete remission (CR) rates were 92% 
in both study arms, but the relapse rate at 2 years was 6% 
in the ATRA plus chemotherapy group versus 16% in the 
sequential group.
  While the survival in most APL patients treated with 
ATRA plus chemotherapy is excellent, relapse or failure to 
achieve molecular remission is observed in 20-30% patients 
[2]. Several pretreatment characteristics of APL patients have 
been identified as having prognostic value [3]. Among them, 
the presenting white blood cell (WBC) count has the highest 
impact on the patient outcome [4].
  The cooperative group PETHEMA (Programa de Estudio y 
Tratamiento de las Hemopatías Maligna) reported a risk- 
adapted treatment strategy of combining ATRA and an-
thracycline monochemotherapy for both induction and con-
solidation, followed by maintenance with ATRA and low- 
dose methotrexate and mercaptopurine [5, 6]. With the pre-
viously used treatment regimen, the number of deaths during 
induction and the relapse rates were higher in patients having 
an elevated WBC [4]. Therefore, PETHEMA recommended 
risk stratification based on the WBC and platelet counts 
at presentation (low-risk group, presenting WBC count of 
≤10×10
9/L and platelet count of ＞40×10
9/L; intermediate- 
risk group, presenting WBC of ≤10×10
9/L and platelets ≤
40×10
9/L; and high-risk group: presenting WBC count of 
＞10×10
9/L). Recently, the French APL 2000 and PETHEMA 
99 trials showed that a cytarabine-containing regimen re-
sulted in a better CR rate and longer survival in patients 
with a high WBC count at presentation [7].
  FLT3 belongs to the class III receptor tyrosine kinase 
family. It is expressed in early hematopoietic progenitors, 
and its dimerization by the FLT3 ligand induces growth-con-
trol signals in normal hematopoiesis. The gene encoding 
FLT3 maps to chromosome band 13q12 [8], and an internal 
tandem duplication (ITD) of the gene (FLT3/ITD) is detected 
in 20-30% of young adults with acute myeloid leukemia 
(AML) [9]. The duplication involves a segment of the juxta-
membrane-domain coding sequence, which is always in- 
frame and frequently involves exon 14 and rarely intron 
14 or exon 15 [9]. FLT3/ITD from AML patients has been 
shown to induce autonomous proliferation in cytokine-de-
pendent cell lines; this finding supports the potential role 
of this mutation in leukemogenesis. AML patients with an 
isolated  FLT3/ITD mutation have poor clinical outcomes, 
similar to those with poor-risk cytogenetic features [9-11]. 
Recent reports suggest that quantitative analysis of FLT3/ITD 
mutation status may be useful to predict the prognosis [10, 
12] and assess the minimal residual disease [13] in AML 
patients.
  The frequency of the FLT3/ITD mutation varies dramati-
cally across cytogenetically and molecularly defined subsets 
of AML and is particularly prevalent in patients with t(15;17) 
[14-16]. Although previous studies on APL patients have 
revealed that the FLT3/ITD mutation is associated with an 
elevated presenting WBC count, hypogranular variant (M3v) 
morphology, and the short (bcr3) isoform of PML-RARA, 
the prognostic significance of FLT3 mutations in APL has 
not been firmly established [14].
　The NPM1 gene frequently acts as a target of chromosomal 
translocations and causes the cytoplasmic dislocation of pro-
teins in various hematological malignancies, thereby indicat-
ing its role in malignant transformation. Mutations in NPM1 
exon-12 are found in approximately 35% of adult AML pa-
tients, and AML with the NPM1 mutation is preferentially 
associated with monocytic differentiation, lack of CD34, nor-
mal cytogenetics, FLT3  gene mutations, and tendency to 
a favorable clinical outcome [17]. In previous studies, how-
ever, NPM1 mutations were not detected in APL patients 
[18, 19].
  In this study, we assessed the treatment outcome of com-
bined ATRA/anthracycline chemotherapy administered as 
induction and consolidation chemotherapy in APL patients 
and investigated a series of uniformly treated APL patients 
to identify the prognostic relevance of various factors present 
at diagnosis.
MATERIALS AND METHODS
1. Patients and treatment protocol
Induction therapy consisted of oral ATRA (45 mg/m
2 per 
day in 2 divided doses), which was maintained for a median 
45 days or until complete hematologic remission and idar-
ubicin (12 mg/m
2 per day) was administered as an intravenous 
bolus on days 2, 4, and 6. Unlike the protocol followed 
in previous studies [5-7], ours did not include administration 
of idarubicin on day 8; this was to eliminate the risk of 
severe myelosuppression during the treatment for remission 
induction. Treatment with ATRA was started as soon as 
APL was diagnosed on the basis of the morphological criteria. 
For patients in whom the diagnosis was not confirmed by 
genetic studies, ATRA treatment was withdrawn, and alter-
native chemotherapy was administered at the physician’s 
discretion. Patients achieving CR received 3 courses of ATRA 
(45 mg/m
2/ d ,  d a y s  1 - 1 5 )  c o m b i n e d  w i t h  r e i n f o r c e d  c o n -
solidation chemotherapy, which consisted of idarubicin (7 
mg/m
2/d for 4 d), mitoxantrone (10 mg/m
2/d for 5 d), and 
idarubicin (12 mg/m
2/d for 2 d). Risk stratification was de-
fined using the WBC and platelet counts at presentation, 
as described in previous studies [5, 6, 20]. For maintenance 
therapy, ATRA (45 mg/m
2/d, days 1-15) was administered 
every 3 months for 2 years. As supportive care, platelets 
were transfused to maintain a platelet count of ＞30×10
9/L 
until resolution of coagulopathy, if any. Once the coagulop-
athy was under control, platelets were transfused only if 
the patient had infectious or hemorrhagic manifestations 
or if the platelet count dropped to below 20×10
9/L. Patients 
with active coagulopathy were treated with fresh frozen 
plasma or cryoprecipitate to maintain the fibrinogen level 
at ＞1.5 mg/L and hemostatic levels of coagulation factors.
2. Cytogenetic analysis/detection of PML-RARA fusion
  All patients were confirmed to have t(15;17) or PML-RARA 
fusion transcript by using conventional cytogenetic techni-Korean J Hematol 2011;46:24-30.
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Table 2. Patient characteristics according to FLT3/ITD mutation 
status (N=50).
FLT3/ITD- FLT3/ITD+  P
No. of patients 40 (80.0%) 10 (20.0%)
Age, median (range) 47 (18-75) yr 51 (40-63) yr 0.331
Aged over 60 yr 5 (12.5%) 2 (20.0%) 0.541
Sex 0.776
Male  18 (45.0%) 4 (40.0%)
Female 22 (55.0%) 6 (60.0%)
FAB subtypes 0.098
Typical 39 (97.5%) 8 (80.0%)
Variant 1 (2.5%) 2 (20.0%) 
WBC, ×10
9/L,
 median (range)
1.7 (0.5-49.7) 20.4 (0.8-102.8) 0.000
Hb, g/dL,
 median (range)
8.0 (5.0-12.7) 9.9 (6.7-13.9) 0.018
Platelets, ×10
9/L,
 median (range)
36.0 (5.0-135.0) 33.0 (10.0-55.0) 0.306
BM blasts, %,
 median (range)
80.0 (4.0-94.0) 85.5 (70-95) 0.004
Risk group 0.001
Low 13 (32.5%) 1 (10.0%)
Intermediate 20 (50.0%) 1 (10.0%)
High 7 (17.5%) 8 (80.0%)
Abbreviations: WBC, white blood cell; Hb, hemoglobin; BM, bone 
marrow.
Table 1. Demographic data of 53 acute promyelocytic leukemia 
patients.
Median (range)  N (%)
Age 48 (18-75) yr
Aged over 60 yr  7 (13.2)
Sex 
Male 24  (45.3)
Female 29 (53.7)
FAB subtypes
Typical 49 (92.5)
Variant 4 (7.5)
WBC, ×10
9/L 2.0 (0.5-102.8)
Hb, g/dL 8.0 (5.0-13.9)
Platelets, ×10
9/L 33.0 (5.0-135.0)
BM blasts, % 83 (4-95)
Risk group
Low 14 (26.4)
Intermediate 23 (43.4)
High 16 (30.2)
FLT3/ITD+
(available in 50 patients)
10 (20.0)
Abbreviations: FAB, French-American-British; WBC, white blood 
cell; Hb, hemoglobin; BM, bone marrow.
ques or nested reverse transcriptase-polymerase chain re-
action (RT-PCR), respectively.
3. Mutational analysis
  Genomic DNA was extracted from cells, such as cry-
opreserved mononuclear cells, which were harvested from 
B M  s a m p l e s  b y  u s i n g  a  Q I A a m p  D N A  B l o o d  M i n i  K i t  
(QIAGEN, Valencia, CA, USA), according to the manufacturer’s 
protocol. For FLT3/ITD mutational analysis, wild-type FLT3 
gene exon 11 and 12 were amplified by genomic PCR using 
the primers 5'-CAATTTAGGTATGAAAGCC-3' (sense) and 
5'-CTTTCAGCATTTTGACGGCAACC-3' (anti-sense). Each 
reaction contained 2.5 mM dNTP, 2.5 mM MgCl2, 0.5 μM 
of each primer, and 0.5 U f-Taq polymerase in a total volume 
of 20 μL. Samples were amplified by initial denaturation 
at 95
oC for 5 min, followed by 35 cycles of 94
oC for 30 
s, 53
oC for 1 min, and 72
oC for 2 min, with a final 10-min 
extension at 72
oC. PCR products (10 μL) were resolved on 
6% polyacrylamide gels, stained with ethidium bromide, 
and photographed under ultraviolet light.
  For NPM1 mutational analysis, NPM1 gene exon-12 was 
amplified by genomic PCR using the primers 5'-TCTGAGTAT 
AAATTTTCTTGGAGTCA-3' (sense) and 5'-ACCAAGCAAA 
GGGTGGAGTT-3' (anti-sense). The reaction contained 1.25 
pmol of each primer, 50 ng genomic DNA, 250 μM dNTPs, 
and 0.5 U f-Taq polymerase (SolGent, Daejeon, Korea) in 
the buffer provided by the manufacturer. Amplification was 
performed with a PTC 200 thermal cycler (MJ Research, 
Waltham, MA, USA). The PCR fragments were purified using 
the GeneAll PCR Purification Kit (General Biosystem, Seoul, 
Korea). Sequencing reactions were analyzed using an ABI 
3100 sequencer and BigDye Terminator kit (Applied Biosys-
tems, Foster City, CA, USA).
4. Statistical analyses
  CR was defined as per the criteria recommended previously 
[21]. Relapse was defined as the reappearance of blasts after 
CR in peripheral blood or BM. Leukemia-free survival (LFS) 
end points, measured from the date of documented CR, in-
cluded relapse, patient death from any cause, and alive in 
CR at last follow-up (censored). The overall survival (OS) 
end points, measured from the date of diagnosis, were death 
from any cause and alive at last follow-up (censored) [21].
  For intergroup comparisons, Fisher’s exact test (categorical 
data) and the Mann-Whitney U-test (continuous data) were 
used. OS and LFS were analyzed using Kaplan-Meier survival 
curve estimates and log-rank tests to compare the differences 
between the distributions of survival in the patient groups. 
Multivariate analysis using forward conditional selection of 
variables was performed using Cox’s proportional-hazards 
model. A P-value of less than 0.05 was considered to indicate 
statistical significance. All statistical computations were per-
formed using the SPSS software (ver. 18.0; SPSS, Chicago, IL, 
USA).
RESULTS
1. Patient characteristics
　The median age of the 53 APL patients was 48 years 
(range, 18-75 years), with 7 patients being over 60 years. Korean J Hematol 2011;46:24-30.
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Fig. 1. Kaplan-Meier analysis of the APL patients. (A) Overall survival (OS) and (B) leukemia-free survival (LFS).
Table 3. Treatment outcomes according to risk group and FLT3/ITD
status.
N CR (%) P Relapse (%) P
FLT3/ITD 
Wild-type 40 35 (87.5%) 0.034 1 (2.5%) 0.001
Mutated 10 7 (70.0%) 3 (30.0%)
Risk group
Low 14 13 (92.9%) 0.311 0  0.090
Intermediate 23 19 (82.6%) 1 (4.3%)
High 16 13 (81.3%) 3 (18.8%)
Abbreviation: CR, complete remission.
Fig. 2. Kaplan-Meier analysis of APL according to pretreatment risk stratification. (A) Overall survival (OS) and (B) leukemia-free survival (LFS).
Low-, intermediate-, and high-risk groups, according to the 
risk stratification, accounted for 26.4%, 43.4%, and 30.2% 
of the cases, respectively (Table 1). All patients had received 
intensive remission-induction chemotherapy. The median 
follow-up period was 30.8 months (range, 0.2-73.6 months).
　BM samples of 50 patients were evaluated for NPM1 and 
FLT3/ITD mutations. No NPM1 mutation was found in any 
patient, while FLT3/ITD mutations were detected in 10 pa-
tients (20.0%). Details of the presenting features of FLT3/ 
ITD+ patients are provided in Table 2. The median peripheral 
WBC count at diagnosis was significantly higher in FLT3/ 
ITD+ patients than in FLT3/ITD- patients (P＜0.001). The 
number of BM blasts was also higher in FLT3/ITD+ patients 
than in FLT3/ITD- patients (P=0.004). Of the FLT3/ITD+ 
patients, 80% belonged to the high-risk group (P=0.001; Table 
2).
2. Treatment outcome of ATRA combined chemotherapy
  Of the 53 eligible patients, 45 (84.9%) achieved CR. One 
patient (1.9%) showed resistance to induction chemotherapy, 
and the remaining 7 (13.2%) died during the induction 
chemotherapy. Of the 7 early deaths, 3 were due to the 
differentiation syndrome and 4 due to cerebral or pulmonary 
hemorrhage. Four (8.9%) patients had clinical relapse 7- 
15 months after achieving CR. The 3-year Kaplan-Meier Korean J Hematol 2011;46:24-30.
28 Seung-Dok Hong, et al. 
Fig. 3. Kaplan-Meier analysis of APL patients with the FLT3/ITD mutation (FLT3/ITD+) and without the mutation (FLT3/ITD-). (A) Overall survival (OS)
and (B) leukemia-free survival (LFS).
Table 4. Multivariate analyses for leukemia-free and overall survival.
Variables
LFS OS
OR (95% CI) P OR (95% CI) P
FLT3/ITD
Wild-type
Mutated 3.840 
(1.171-12.593)
0.026 3.372 
(0.904-12.573)
0.070
Pretreatment
 risk group
Low
Intermediate 3.396 
(0.396-29.121)
0.265 2.651 
(0.296-23.729)
0.383
High 5.211 
(0.608-44.689)
0.132 3.627 
(0.405-32.471)
0.249
Abbreviations: LFS, leukemia-free survival; OS, overall survival; 
OR, odds ratio; CI, confidence interval.
estimates of OS and LFS were 84.9±4.9% and 77.5±6.0%, 
respectively (Fig. 1). Patients with the hypogranular variant 
subtype did not show a significant difference in the treatment 
outcomes.
3. Prognostic impact of pretreatment risk stratification and 
FLT3/ITD mutations
  With induction chemotherapy, the high-risk group, de-
fined using the WBC and platelet counts at presentation, 
had a lower rate of remission compared to the intermediate- 
and low-risk groups; however, the difference was not statisti-
cally significant (81.3% vs. 82.6% vs. 92.9%, respectively; 
P=0.311;  Table 3). Furthermore, a trend to a higher rate 
of relapse was observed in the high-risk group than in the 
other risk groups, but the difference was not significant 
(18.8% vs. 4.3% vs. 0%; P=0.090; Table 3). The high-risk 
group showed a trend to a lower 3-year LFS (60.0% vs. 
77.1% vs. 92.9%; P=0.229) than the intermediate- and low- 
risk groups (Fig. 2).
　A significant difference was noted between the remission 
rates achieved by induction chemotherapy in patients with 
and without FLT3/ITD mutations (70.0% vs. 87.5%; P=0.034; 
Table 3). Among the patients who achieved CR, the FLT3/ 
ITD+ group had a higher relapse rate than the FLT3/ITD- 
group (30.0% vs. 2.5%; P=0.001). The former also had a 
significantly lower 3-year LFS than the latter (44.4%, vs. 
84.4%; P=0.013). The FLT3/ITD+ group tended to have a 
lower 3-year OS than the FLT3/ITD- group (70.0%. vs. 87.5%; 
P=0.054; Fig. 3), although the difference was not significant.
　Multivariate analysis of the LFS revealed that the FLT3/ 
ITD mutation was independently associated with a shorter 
LFS, after adjusting for pretreatment risk stratification (vs. 
FLT3/ITD-, odds ratio, OR=3.840; P=0.026;  Table 4).
DISCUSSION
  Because the use of the induction regimen with combined 
ATRA and anthracycline chemotherapy resulted in high CR 
rates and good disease-free survival (DFS), the inclusion of 
cytarabine in addition to daunorubicin or idarubicin for APL 
patients is considered to have no impact on the treatment 
outcome [20]. Thus, since many years, ATRA combined with 
anthracycline monochemotherapy has been used as a stand-
ard treatment for APL. In this study, we assessed the clinical 
outcome of APL patients treated with ATRA combined with 
anthracycline chemotherapy.
　Previous studies on the use of combined ATRA and chemo-
therapy without cytarabine for the treatment for newly diag-
nosed APL showed CR rates ranging from 81 to 95% [1, 
20]; the CR rate in this study was 84.9%. Because only 
1 patient showed resistance to the induction chemotherapy Korean J Hematol 2011;46:24-30.
ATRA combination and FLT3-ITD in APL 29
regimen, the inferior treatment outcome of our study seemed 
to result from the high rates of early death during the in-
duction chemotherapy due to fatal bleeding or differentiation 
syndrome; this suggests that early awareness and manage-
ment of such complications are important.
　This study also demonstrated that the patients in the 
high-risk group, based on the WBC and platelet counts at 
presentation, tended to have poorer clinical outcomes, such 
as lower CR rates, higher relapse rates, and shorter LFS, 
as compared to those in the low- or intermediate-risk groups; 
however, the difference between the groups was not statisti-
cally significant.
　In this series of APL patients, we evaluated the prevalence 
and clinical impact of NPM1 and FLT3/ITD mutations. As 
was the case in previous studies [18, 19], none of the 50 
patients evaluated in this study harbored the NPM1 mutation, 
while 20% exhibited FLT3/ITD mutations. The reported fre-
quency of FLT3/ITD mutations varies among studies, from 
12 to 38% [22-25]. In comparison with the data from Western 
countries, the reported incidence of FLT3/ITD mutations 
in APL patients is lower in Asian countries such as in Japan 
and Taiwan (20 and 21%) [24, 25]. For Korea, one study 
on the prevalence of FLT3/ITD mutations in APL patients 
reported a prevalence of 12% [22]; the results obtained in 
this study were similar to those reported from other Asian 
countries. The striking differences in the relative incidence 
of FLT3/ITD between APL patients in Europe/North America 
and Asia are noteworthy, and the significantly varying pro-
pensity for the disease to develop in different ethnic groups 
[23] suggests that genetic and/or environmental influences 
play a role in the pathogenesis of APL.
　While the prognostic implications of the FLT3/ITD muta-
tion status in cytogenetically normal AML are well described 
[9-11], the prognostic relevance of this mutation in APL 
patients is less clear. The current literature on the effect 
of FLT3 mutations on the outcome in APL is conflicting. 
Some studies found that the FLT3 status did not result in 
any apparent difference in DFS [14], whereas others reported 
that FLT3/ITD mutations were associated with a tendency 
towards [26, 27] or significantly inferior [28] LFS. In our 
study, an association between the FLT3/ITD mutation and 
elevated presenting WBC and BM blast counts was noted 
in APL patients. A previous study indicated that FLT3 alter-
ations in APL are associated with more aggressive clinical 
features and suggested that these lesions may not play a 
major role in leukemia progression [26]. However, in vitro 
studies of small-molecule FLT3 inhibitors have shown that 
they can suppress the survival and proliferation of FLT3/ITD+ 
AML blast cells [29, 30]. In our study, patients carrying 
this mutation had a lower CR rate, higher rate of relapse, 
and shorter LFS and OS than those without this mutation. 
Although the FLT3/ITD mutation was associated with high 
WBC and BM blast counts at presentation, multivariate anal-
ysis showed that this mutation was an independent predictor 
of LFS in APL patients.
　In summary, our study examined the clinical outcome 
of combined ATRA and anthracycline chemotherapy in newly 
diagnosed APL patients. Patients with FLT3/ITD mutations 
showed more aggressive clinical features. Further, the FLT3/ 
ITD mutation at diagnosis characterizes a small subgroup 
of patients with extremely poor prognosis. Thus, to increase 
the cure rates, it would be helpful to identify patients with 
high-risk disease, such as those carrying FLT3/ITD mutations, 
who could benefit from treatment modification, including 
the addition of cytarabine or FLT3 inhibitors.
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